Fractyl Health, Inc. (GUTS)

Fractyl Health's stock has experienced significant volatility and a general decline over the past year. In January 2026, the company announced positive data from its REMAIN-1 Midpoint Cohort, but the stock plummeted. In March 2026, Fractyl Health reported its Fourth Quarter and Full Year 2025 financial results and received a Nasdaq notice of non-compliance with the minimum bid price requirement. In February 2026, the company completed randomization in the REMAIN-1 Pivotal Cohort. Fractyl Health is scheduled to report its First Quarter 2026 financial results and participate in an investor conference in May 2026.

The demand for Fractyl Health's products and services is unlikely to exhibit significant seasonality, as chronic diseases require ongoing management and treatment irrespective of the time of year. Demand for Revita and Rejuva would likely be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access rather than seasonal patterns.

Fractyl Health, Inc. is a clinical-stage metabolic therapeutics company focused on developing innovative treatments for obesity and type 2 diabetes. Its core business revolves around pioneering therapies that address the root causes of metabolic diseases. The company's major product candidates include the Revita DMR System, an outpatient procedural therapy designed to modify duodenal dysfunction, and Rejuva, a novel pancreatic gene therapy platform in preclinical development.

Fractyl Health, Inc. is headquartered in Burlington, Massachusetts, United States. The Revita device has been commercially available in the UK since January 2020 and in Germany since early 2023.

Fractyl Health's brand reputation appears mixed, influenced by promising clinical data and stock price fluctuations. The average analyst recommendation is "Hold". Positive clinical data from the REVEAL-1 and REMAIN-1 trials reinforce Revita's potential. A significant stock price drop in January 2026 and a Nasdaq non-compliance notice could negatively impact investor confidence.

Fractyl Health, Inc. has significant institutional ownership, accounting for approximately 71.06% of the shares outstanding, while insider ownership is around 0.48%. Major institutional shareholders include Nantahala Capital Management, LLC, Silverarc Capital Management, LLC, and 683 Capital Management, LLC. CEO Harith Rajagopalan owns 0.8% of the company's shares, and the general public holds a 23% stake.